Bevacizumab

You have access
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
DANIEL KREJCI, PETR OPALKA, JANA KREJCI, MILADA ZEMANOVA, PETRA ZEMANOVA, JURAJ KULTAN, ONDREJ FISCHER, JANA SKRICKOVA, MONIKA BRATOVA, MARKETA CERNOVSKA, MICHAL HRNCIARIK, HELENA COUPKOVA, KAROLINA HURDALKOVA, MAGDA BARINOVA, LEONA KOUBKOVA, DANIEL DOLEZAL, MARTIN SAFANDA, MILOS PESEK and MARTIN SVATON

Anticancer Research May 2021, 41 (5) 2597-2603; DOI: https://doi.org/10.21873/anticanres.15039
You have access
Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy
MARTIN SVATON, JIRI BLAZEK, GABRIELA KRAKOROVA, MILOS PESEK, MARCELA BURESOVA, ZUZANA TEUFELOVA, JOSEF VODICKA, KAROLINA HURDALKOVA, MAGDA BARINOVA and ONDREJ TOPOLCAN

Anticancer Research April 2021, 41 (4) 2053-2058; DOI: https://doi.org/10.21873/anticanres.14974
You have access
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
TETSUO ISHIZAKI, JUNICHI MAZAKI, MASANOBU ENOMOTO, MASATOSHI SHIGOKA, KENTA KASAHARA, TAKAAKI MATSUDO, HIDEAKI KAWAKITA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA

Anticancer Research April 2021, 41 (4) 2157-2163; DOI: https://doi.org/10.21873/anticanres.14988
You have access
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept
YUNAMI YAMADA, NOBUHISA MATSUHASHI, HIRONORI FUJII, AKITAKA MAKIYAMA, HIROTOSHI IIHARA, TAKAO TAKAHASHI, DAICHI WATANABE, SHIGERU KIYAMA, RYO KOBAYASHI, AKIO SUZUKI and KAZUHIRO YOSHIDA

Anticancer Research January 2021, 41 (1) 533-541; DOI: https://doi.org/10.21873/anticanres.14805
You have access
Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study
TERUMI TANIGAWA, MAKI MATODA, MAKIKO OMI, YOICHI AOKI, SACHIHO NETSU, HIDETAKA NOMURA, SANSHIRO OKAMOTO, KOHEI OMATSU, MAYU YUNOKAWA, HIROYUKI KANAO and NOBUHIRO TAKESHIMA

Anticancer Research September 2020, 40 (9) 5285-5290; DOI: https://doi.org/10.21873/anticanres.14533
You have access
Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer
MASATSUNE SHIBUTANI, HISASHI NAGAHARA, TATSUNARI FUKUOKA, YASUHITO ISEKI, EN WANG, YUKI OKAZAKI, SHINICHIRO KASHIWAGI, KIYOSHI MAEDA, KOSEI HIRAKAWA and MASAICHI OHIRA

Anticancer Research July 2020, 40 (7) 4157-4163; DOI: https://doi.org/10.21873/anticanres.14415
You have access
A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
HIRONORI YOSHIDA, YOUNG HAK KIM, YUICHI SAKAMORI, HIROKI NAGAI, HIROAKI OZASA, TOSHIHIKO KANEDA, HIROSHIGE YOSHIOKA, HIROAKI NAKAGAWA, KEISUKE TOMII, ASUKA OKADA, KENICHI YOSHIMURA, MASATAKA HIRABAYASHI and TOYOHIRO HIRAI

Anticancer Research May 2020, 40 (5) 2981-2987; DOI: https://doi.org/10.21873/anticanres.14278
You have access
Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group
GIANNIS MOUNTZIOS, XANTHIPPI MAVROPOULOU, GEORGIA-ANGELIKI KOLIOU, HELENA LINARDOU, EPAMINONTAS SAMANTAS, PARIS KOSMIDIS, GEORGE FOUNTZILAS, APHRODITE CHARITANDI and ANNA KALOGERA-FOUNTZILA

Anticancer Research April 2020, 40 (4) 2095-2106; DOI: https://doi.org/10.21873/anticanres.14168
You have access
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study
ANGIOLO GADDUCCI, STEFANIA COSIO, ANDREA ALBERTO LISSONI, VALENTINA ZIZIOLI, MARCO ADORNI, ANNA MARIA FERRERO, FABIO LANDONI and ENRICO SARTORI

Anticancer Research March 2020, 40 (3) 1543-1550; DOI: https://doi.org/10.21873/anticanres.14100
You have access
Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC
HISAO IMAI, KYOICHI KAIRA, ICHIRO NARUSE, NORIMITSU KASAHARA, YOSUKE KAMIDE, AKIHIRO ONO, TOMOMI MASUDA, NORIAKI SUNAGA, KOICHI MINATO and TAKESHI HISADA

Anticancer Research March 2020, 40 (3) 1571-1578; DOI: https://doi.org/10.21873/anticanres.14104

Main menu

User menu

Search

Bevacizumab

Pages